graph Evidence gap map comparisons
ipilimumab based treatmentipilimumab aloneipilimumab based treatmentanti-CTLA-4atezolizumab based treatmentnivolumab based treatmentanti-PD-(L)1pembrolizumab based treatmentpembrolizumab alonepembrolizumab based treatmentImmune checkpoint association
ipilimumab alone Ipilimumab (10 mg/kg) ipilimumab plus gp100 ipilimumab plus SoC tremelimumab atezolizumab plus cometinib atezolizumab plus SoC nivolumab alone nivolumab followed by ipilimumab pembrolizumab alone pembrolizumab (10mg/kg) pembrolizumab (10mg/kg) 2 weeks pembrolizumab (2mg/kg) pembrolizumab plus SoC nivolumab plus ipilimumab relatlimab plus nivolumab
mML - (neo)adjuvant (NA)
mML - NA - all population 9              
mML - NA - PDL1 positive 1   
mML - 1st line (L1)
mML - L1 - all population 7            
mML - L1 - BRAF mutant 2     
mML - L1 - BRAF wild 3       
mML - 2nd line (L2)
mML - L2 - all population 11                    
mML - L2 - BRAF mutant 1   
Comparator:  vs ipilimumab alone;   vs ipilimumab followed by nivolumab;   vs nivolumab alone;   vs Standard of Care (SoC);   vs placebo plus SoC;   vs pembrolizumab alone;   vs dacarbazine;   vs gp100;   vs interferon alpha;   vs placebo;   vs Ipilimumab (10 mg/kg); 
Risk of bias:  low;   some concerns;   high;  NA;